Where is BioMarin Pharmaceutical (BMRN) Headed According to Analysts?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best biotech stocks with high potential. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reported total revenues of $825 million in fiscal Q2 2025, up 16% year-over-year and up 17% year-over-year at constant currency. GAAP diluted earnings per share (EPS) for the quarter reached $1.23.

In a report released on September 17, Christopher Raymond from Raymond James maintained a Buy rating on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and set a price target of $85.00.

In addition to Raymond James, Wedbush’s Yun Zhong also expressed bullish sentiments for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in a report released on September 8, assigning the stock a Buy rating. However, the same day, H.C. Wainwright initiated coverage of the stock with a Hold rating and a $60 price target.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

While we acknowledge the potential of BMRN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.